Business
Controlling Shareholder of MedMira Announces Name Change and Addition of New Partners to Its Board
HALIFAX, Sept. 26, 2012 /CNW/ - MedMira Inc., (MedMira) (TSXV: MIR), a developer of rapid d...
About this update from Medmira Inc.
[{"type":"text","content":"\n\n\n\n\n\nHALIFAX, Sept. 26, 2012 /CNW/ - MedMira Inc., (MedMira) (TSXV: MIR), a\n developer of rapid diagnostic technology and solutions, announced today\n that its largest and controlling shareholder, Andurja Beteiligungen AG\n has changed its name to OnSite Lab Holding AG (OnSite Lab).  OnSite Lab\n has further partnered with a Luxembourg-based investment fund,\n Redalpine Capital II S.C.S., SICAR (Redalpine Capital), and a private\n investment company, RLG APS, located in Copenhagen to enhance its Board\n and investment focus in life science companies.\n\n\n\"The substantial investment we have made in MedMira represents our\n strong commitment, our focus, and a key element of our strategic plan.\n By changing our company's name to OnSite Lab Holding AG, we are moving\n a step closer to building an even stronger affiliation with MedMira. We\n are bringing the expertise of Redalpine and RLG APS on to our Board to\n provide additional industry capabilities to MedMira.  Dr. Michael\n Sidler, partner at Redalpine Capital, has a wealth of experience in the\n life sciences and diagnostics industry and in linking science and\n business entities.  RLG APS is led by Dr. H.P. Richard, a well\n established Swiss medical doctor will offer further assistance to\n MedMira for its expansion into new business opportunities and financing\n networks. We are committed to work with the Company's management and\n its Board to deliver the best value to all stakeholders of MedMira,\"\n said Urs Meile, Chairman of OnSite Lab Holding AG.\n\n\nMeile continued, \"Our investment in MedMira is a chance to be a part of\n an evolutionary shift in the rapid diagnostics market.  We see MedMira\n as an investment that not only covers the humanitarian side but it is\n our strong belief that MedMira is one of the very few companies that\n will yield a high return on investment in today's market.\"\n\n\n\"We are excited about the in-depth life sciences and diagnostics\n industry knowledge, and business network brought by Dr. Sidler and Dr.\n Richard through OnSite Lab.  We believe that their expertise will be\n invaluable in optimizing MedMira's strategic direction during the next\n phase of our growth,\" said Hermes Chan, CEO, MedMira Inc.\n\n\nDr. Sidler has been nominated as the board representative for OnSite Lab\n on MedMira's Boa...